This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yue, J.
Right arrow Articles by Wang, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yue, J.
Right arrow Articles by Wang, H.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2003, p. 2209-2212, Vol. 41, No. 5
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.5.2209-2212.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Mutations in the rpoB Gene of Multidrug-Resistant Mycobacterium tuberculosis Isolates from China

Jun Yue,1,2 Wei Shi,1,3 Jingping Xie,1 Yao Li,1,3 Erliang Zeng,1,3 and Honghai Wang1*

State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University,1 Shanghai Pneumology Hospital, Shanghai 200433,2 Shanghai Institute of Biostar Genechip, Shanghai 200092, People's Republic of China3

Received 11 September 2002/ Returned for modification 18 November 2002/ Accepted 4 February 2003


arrow
ABSTRACT
 
Mutations in the 81-bp rifampin resistance determining region (RRDR) and mutation V176F locating at the beginning of the ropB gene were analyzed by DNA sequencing of 86 Mycobacterium tuberculosis clinical isolates (72 resistant and 14 sensitive) from different parts of China. Sixty-five mutations of 22 distinct kinds, 21 point mutations, and 1 insertion were found in 65 of 72 resistant isolates. The most common mutations were in codons 531 (41%), 526 (40%), and 516 (4%). Mutations were not found in seven (10%) of the resistant isolates. Six new alleles within the RRDR, along with five novel mutations outside the RRDR, are reported. None of isolates contained the V176 mutation.


arrow
TEXT
 
Tuberculosis (TB) remains one of the main threats to humans, causing 8 million new cases and 2 million deaths each year. The problem is becoming more critical with the emergence and spread of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, defined as resistant to at least isoniazid and rifampin (RIF). About 2 to 3% of all new TB cases worldwide are due to MDR strain, and the highest MDR populations among new cases have been found in China (11%) and eastern Europe (7 to 14%) (1, 6, 7). China is not only one of the 22 high-burden countries that collectively account for ca. 80% of the world's TB cases but it is also the hotspot area of very high prevalence of MDR TB identified by the World Health Organization (4, 5). Because of the very large financial implications of the treatment and spread of MDR strains due to globalization, MDR TB has been classified as a global pandemic more deadly than AIDS, with the potential to destabilize society.

RIF is one of the principal first-line drugs used in combination chemotherapy and RIF resistance (Rifr) is a valuable surrogate marker of MDR TB (3). RIF interferes with transcription and elongation of RNA by binding to the ß-subunit of RNA polymerase. It has been observed that >90% of Rifr strains of M. tuberculosis possess genetic alterations within an 81-bp fragment, the so-called Rifr-determining region (RRDR), of the rpoB gene, which codes for the beta subunit of the RNA polymerase (17). The types of mutations include single-nucleotide changes and deletions and insertions.

Compilation of data available from many studies indicated that Rifr clinical isolates of M. tuberculosis from diverse geographic regions had 87 distinct point mutations or short insertions and deletions located in an 81-bp core RRDR of rpoB codons 507 to 533 encoding 27 amino acids (2, 11, 12, 14-16, 18, 19, 21). Few of these findings are associated with Chinese isolates. Therefore, the aim of the present study was to characterize mutations in the RRDR of the rpoB gene by DNA sequencing, the prevalence of the recently described mutation V176F (10), located at the beginning of the rpoB gene and associated with Rifr, was also determined. A total of 72 MDR M. tuberculosis isolates from five provinces of China (Guangxi Zhuang autonomous region [GX], Jilin [JL], Zhejiang [ZJ], Jiangsu [JS], and Anhui [AH]). GX is located in the southern region. ZJ, JS, and AH are located in the eastern region. JL is located in the northern region.

M. tuberculosis isolates. A total of 72 Rifr.and 14 RIF-sensitive (Rifs) strains were recovered from 86 patients from five province in China. Of the 72 Rifr strains, the numbers isolated from each province were as follows: GX, 26; JL, 16; ZJ, 15; JS, 8; and AH, 7. Of the 14 Rifs strains, 5 were collected from GX, 4 were collected from JL, and 5 were collected from ZJ.

Drug susceptibility testing. Drug susceptibility was determined on Lowenstein-Jensen medium by absolute concentration method and/or the modified proportion method in a Bactec 460TB apparatus in accordance with the manufacturer's instructions. RIF sensitivity was determined again by the MIC method with serial dilutions of RIF. Resistance was defined by an MIC of >=128 mg/liter. The drug susceptibility profiles of these isolates are shown in Table 1.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Drug susceptibility patterns of MDR M. tuberculosis strains isolated in China

Sequencing of rpoB. Two regions of rpoB associated with Rifr were sequenced after amplication by PCR. Template DNA for PCR was prepared by chloroform-isoamyl alcohol extraction as previously described (8). Two oligonucleotide primers designed by Primer 5 software, rpoB101F (5'-TACGGTCGGCGAGCTGATCC-3') and rpoB101R (5'-TACGGCGTTTCGATGAACC-3'), were used to amplify a 411-bp fragment of the rpoB gene, from nucleotides 2201 to 2611 (GenBank accession no. L27989), containing the 81-bp hypervariable region. For analysis of the presence of the V176F mutation, a 365-bp fragment of the rpoB gene was amplified by using primers TB-176-F (5'-CTTCTCCGGGTCGATGTCGTTG-3') and TB-176-R (5'-CGCGCTTGTCGACGTCAAACTC-3') as recently described by Heep et al. (10). The PCR product was sequenced by using a Prism 377 automated DNA sequencer (Applied Biosystems, Inc., Foster City, Calif.). For each sample, the sequence was examined twice in one direction by using as a template the products of two independent amplification reactions. The isolates that showed new mutations were sequenced again by cloning PCR products into the M13 plasmid. Sequence data were assembled and analyzed by CLUSTAL W.

IS6110-based restriction fragment-length polymorphism (RFLP). PvuI-digested DNA of M. tuberculosis was probed with the insertion element IS6110 according to the standardized protocol of van Embden et al. (22).

Mutations in the ropB gene of Rifr M. tuberculosis isolates from GX. In this group, DNA sequence analysis of 26 resistant isolates showed that 24 had 9 different kinds of missense mutations within a 411-bp region of the rpoB gene containing 81-bp RRDR. All isolates had a single point mutation, and the highest frequency of mutation was observed in the codon 526 (50%). Point mutations in codons 531 (35%), 516 (8%), and 511 (4%) were also observed. No mutations were found in the 411-bp rpoB segment from two Rifr isolates and five Rifs isolates.

Mutations in the rpoB gene of Rifr M. tuberculosis isolates from JL. Twenty M. tuberculosis isolates (16 Rifr and 4 Rifs) were analyzed. Single-point mutations were found in 14 of 16 Rifr isolates. Six different kinds of nucleotide substitution were detected in three codons of RRDR in the rpoB gene. Mutations in codon 531 (50%), 526 (31%), and 522 (6%) were also detected. Two M. tuberculosis Rifr isolates contained no mutations within the region of rpoB gene examined. No mutations were observed in the Rifs isolates.

Mutations in the rpoB gene of Rifr M. tuberculosis isolates from the eastern region (ZJ, AH, and JS). DNA sequence analysis of the 30 Rifr isolates from eastern region of China showed that 23 had a single mutation, two had double mutations, and two had quadruple mutations in the 411-bp fragment of the ropB gene. Three isolates did not contain any mutation. Eighteen kinds of mutation, seventeen point muatations, and one insertion were observed in the 81-bp RRDR of the ropB gene. Most mutations occurred in codons 531 (40%) and 526 (30%). Two isolates from ZJ that contained four mutations had four novel mutations. One of the two isolates had mutations at codon 505 (TTC to TCC), codon 522 (TCG to CCG), codon 526 (CAC to CGC), and codon 531 (TCG to TTG), whereas the other shows changes in codon 500 (GCC to GTC), codon 507 (GGC to GGT), codon 518 (AAC to TAC), and codon 538 (CTG to CCG). Two Rifr isolates from JS contained point mutations in two separate codons, resulting in two amino acid substitutions for each isolate (506 and 507, 502 and 526). None of the five sensitive strains contained any mutation.

General analysis. The MICs of RIF for all 72 Rifr isolates were >128 mg/liter, whereas the MICs of RIF for all 14 Rifs isolates were <32 mg/liter. The analysis of 72 Rifr isolates revealed that 65 had mutations within a 411-bp fragment of the rpoB gene (Fig. 1). Twenty-two different types of mutations were identified in the 81-bp RRDR of the rpoB gene among 72 Rifr M. tuberculosis clinical isolates, and six new alleles were identified (Table 2). Most of them were single-nucleotide mutations (90%) involving nine codons, whereas only one isolate had an insertion. The codons most frequently affected by point mutations were 531, 526, and 516, with frequencies of 41, 40, and 5%, repectively. No mutations were revealed in the rpoB segment sequenced from 14 Rifr isolates. Seven Rifr isolates (10%) contained no mutations in this sequenced region, although these isolates were resistant to RIF as determined by the MIC method. The V176F mutation could not be found in the beginning of the ropB gene in all organisms.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1. Mutations located in the RRDR of the M. tuberculosis rpoB gene in 65 Rifr isolates from China. The bottom panel shows the mutated codons with corresponding amino acids. The original sequence is boxed. Numbers to the left or below amino acid designations indicate numbers of isolates showing the mutation, while the percentages denote the frequencies of occurrence of mutations at the particular codon.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Distribution of mutations found in the RRDR of the rpoB gene in Rif M. tuberculosis isolates from China

In our study, we observed that 90% of the M. tuberculosis isolates with the Rifr phenotype contained missense mutations that led to amino acid substitutions at the Ser-531 (41%), His-526 (40%), and Asp-516 (5%) residues. This finding is similar to results reported by Ramaswamy and Musser, who determined frequencies of 41 and 36% for various mutations occurring at codons 531 and 526, respectively, in 478 isolates obtained from various parts of the world (17). Although Qian et al. (16) reported a low frequency of the mutation at codon 526 (4%) in China isolates, we found a high frequency of this mutation (40%). Similarly high frequencies of this mutation at codon 526 have found in isolates from Korea (38%) (13), Japan (33%) (16), Italy (30%) (15), and Greece (19%) (14). The likelihood of a mutation at codon 526 is higher than at codon 531 in isolates from GX. There was no specific geographical clustering of isolates in terms of mutations. Analysis with a large number of samples is the only way to reach definitive conclusions.

Six new alleles within the RRDR, along with five novel mutations outside the RRDR, were recognized in this investigation. New alleles include mutations from GGC (Gly) to GGT (Gly) at codon 507, AAC (Asn) to TAC (Tyr) at codon 518, TCG (Ser) to CCG (Pro) at codon 522, CAC (His) to GCC (Ala) at codon 526, TCG (Ser) to TAC (Tyr) at codon 531, and CTG (Leu) to CCG (Pro) at codon 533. New mutations outside the RRDR were seen in four isolates with double or multiple mutations (GCC to GTC at codon 500, ATC to GTC at codon 502, TTC to TCC at codon 505, TTC to TTT at codon 506, and CTG to CCG at codon 538). Similar findings were reported worldwide. (2, 14, 18, 23).

In contrast to results revealed by Taniguchi et al. (20), who suggest a strong correlation of specific amion acid substitutions and MIC, our results showed high MICs for two isolates with a mutation at codon 514 (MIC = 256 mg/liter) or codon 533 (MIC = 512 mg/liter). Similar findings were reported by Cheruvu et al. (2).

No mutations were detected in V176 residue of the rpoB gene from these isolates. Mutation V176 appears to confer high-level resistance in clinical M. tuberculosis isolates and may account for >1% of all Rifr strains (9). No mutation V176 was detected in the present study; an inadequate number of samples may be the reason. Another possibility is that these strains lack the V176 mutation.

Ten percent of Rifr M. tuberculosis isolates in the present study did not show any mutation in the RRDR and the V176 codon of rpoB gene. These results differ from the data showing that only ~4% of the Rifr isolates lack RRDR changes. We retested the resistance of these isolates to RIF, and the results that demonstrated our drug sensitivity test is reliable and accurate. The presence of a mutation outside the regions investigated in this gene or mutation of these genes whose products participate in antibiotic permeation or metabolism or some other resistant mechanism, such as unexplained resistance or heteroresistance, may account for the Rifr phenotype in these isolates. The alarmingly high percentage of isolates lacking mutations seems to represent an important impediment to molecular drug resistance testing. The currently available molecular methods are designed to determine the expected mutations within the RRDR of the rpoB gene. Therefore, although the molecular methods may aid in the rapid detection of mutations associated with drug resistance, the tested results must always be confirmed by phenotypic methods.

Knowing the strain genotype would distinguish whether this rare mutation occurred twice in two populations or happened once and then spread to another region. We analyzed 40 isolates of M. tuberculoisis in which the mutation of the rpoB gene was observed more than once by IS6110 RFLP. Most of isolates shared 8 to 21 copies. There were 37 unique fingerprints. A total of 27 (68%) of 40 isolates had an IS6110-based banding pattern characteristic of the Beijing genotype of M. tuberculosis. This Beijing family of isolates was highly related to MDR. Some isolates with the same point mutation in the rpoB gene from two provinces had different IS6110 patterns, suggesting that there was no direct transmission within regions. Two isolates with similar IS6110 fingerprints have different mutations in rpoB. rpoB genotyping can also be used to discriminate between Rifr M. tuberculosis isolates with identical IS6110 fingerprints.

In conclusion, the analysis of the 81-bp RRDR and V176 of the rpoB gene of 86 M. tuberculosis clinical isolates from various parts of China was performed and mutations were recognized. Six new alleles and five novel mutations were recognized. The profile of mutations in the 81-bp RRDR is similar to that of the majority of isolates worldwide. More information about these mutations would be helpful in the development of novel molecular diagnostic methods such as the DNA line probe and DNA microarray, which will be implemented in China. The high percentage of Rifr isolates with no mutations suggests that phenotypic methods remain an important complement to genotypic methods for drug susceptibility testing.

Nucleotide sequence accession numbers. The sequences with mutations in the new alleles are deposited in GenBank under accession numbers AY147213, AY147214, AY147215, AY147216, AY147217, and AY147218. Those with mutations outside RRDR are deposited under accession numbers AY147208, AY147209, AY147210, AY147211, and AY147212.


arrow
ACKNOWLEDGMENTS
 
This investigation received financial support from the China National 973 project (2002 CB512804).


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: State Key Laboratory of Genetic Engineering Institute of Genetics, Fudan University, 220 Handan Rd., Shanghai 200433, People's Republic of China. Phone: (8621) 65643777. Fax: (8621) 65648376. E-mail: hhwang{at}fudan.edu. Back


arrow
REFERENCES
 
    1
  1. Becerra, M. C., J. Bayona, J. Freeman, P. E. Farmer, and J. Y. Kim. 2000. Redefining MDR-TB transmission-drug resistance "hot spots." Int. J. Tuberc. Lung Dis. 4:387-394.[Medline]
    2. 2
  2. Cheruvu, M., N. Selvakumar, S. Narayanna, and P. R. Narayanan. 2001. Mutations in the rpoB gene of multidrug-resistance Mycobacterium tuberculosis clinical isolates from India. J. Clin. Microbiol. 39:2987-2990.[Abstract/Free Full Text]
    3. 3
  3. Drobniewski, F. A., and S. M. Wilson. 1998. The rapid diagnosis of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a molecular story. J. Med. Microbiol. 47:189-196.[Abstract/Free Full Text]
    4. 4
  4. Dye, C., and B. G. Williams. 2000. Criteria for the control of drug-resistant tuberculosis. Proc. Natl. Acad. Sci. USA 97:8180-8185.[Abstract/Free Full Text]
    5. 5
  5. Dye, C., S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione. 1999. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. W.H.O. Global Surveillance and Monitoring Project. JAMA 18:677-686.
    6. 6
  6. Dye, C., B. G. Williams, M. A. Espinal, and M. C. Raviglione. 2002. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295:2042-2046.[Abstract/Free Full Text]
    7. 7
  7. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, and M. C. Raviglione. 2001. Global trends in resistance to antituberculosis drugs. N. Engl. J. Med. 344:1294-1303.[Abstract/Free Full Text]
    8. 8
  8. Goyal, M., and D. Young. 1998. Molecular approaches in Mycobacterium tuberculosis and other infections caused by Mycobacterium species, p. 157-190. In N. Woodford and A. P. Johnson (ed.), Molecular bacteriology: protocols and clinical applications. Humana Press, Inc., Totowa, N.J.
    9. 9
  9. Heep, M., B. Brandstatter, U. Rieger, N. Lehn, E. Richter, S. Rusch-Gerdes, and S. Niemann. 2001. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 39:107-110.[Abstract/Free Full Text]
    10. 10
  10. Heep, M., U. Rieger, D. Beck, and N. Lehn. 2000. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:1075-1077.[Abstract/Free Full Text]
    11. 11
  11. Hirano, K., C. Abe, and M. Takahashi. 1999. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J. Clin. Microbiol. 37:2663-2666.[Abstract/Free Full Text]
    12. 12
  12. Kapur, V., L.-L. Li, S. Iordanescu, M. R. Hamrick, A. Wanger, B. N. Kreiswirth, and J. M. Musser. 1994. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 32:1095-1098.[Abstract/Free Full Text]
    13. 13
  13. Kim, B.-J., S.-Y. Kim, B.-H. Park, et al. 1997. Mutations in the ropB gene of Mycobacterium tuberculosis that interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing. J. Clin. Microbiol. 35:492-494.[Abstract]
    14. 14
  14. Matsiota-Bernard, P., G. Vrioni, and E. Marinis. 1998. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece. J. Clin. Microbiol. 36:20-23.[Abstract/Free Full Text]
    15. 15
  15. Pozzi, G., M. Meloni, E. Iona, G. Orru, O. F. Thoresen, M. L. Ricci, M. R. Oggioni, L. Fattorini, and G. Orefici. 1999. rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J. Clin. Microbiol. 37:1197-1199.[Abstract/Free Full Text]
    16. 16
  16. Qian, L., C. Abe, T. P. Lin, M. C. Yu, S. N. Cho, S. Wang, and J. T. Douglas. 2002. rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J. Clin. Microbiol. 40:1091-1094.[Abstract/Free Full Text]
    17. 17
  17. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc. Lung Dis. 79:3-29.[CrossRef][Medline]
    18. 18
  18. Schilke, K., K. Weyer, G. Bretzel, B. Amthor, J. Brandt, V. Sticht-Groh, P. B. Fourie, and W. H. Haas. 1999. Universal pattern of rpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa. Int. J. Tuberc. Lung Dis. 3:620-626.[Medline]
    19. 19
  19. Sintchenko, V., W. K. Chew, P. J. Jelfs, and G. L. Gilbert. 1999. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology 31:257-260.[CrossRef][Medline]
    20. 20
  20. Taniguchi, H., H. Aramaki, Y. Nikaido, Y. Mizuguchi, M. Nakamura, T. Koga, and S. Yoshida. 1996. Rifampin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 144:103-108.[CrossRef][Medline]
    21. 21
  21. Valim, A. R., M. L. Rossetti, M. O. Ribeiro, and A. Zaha. 2000. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J. Clin. Microbiol. 38:3119-3122.[Abstract/Free Full Text]
    22. 22
  22. van Embden, J. D., M. D. Cave, J. T. Crawford, J. W. Dale, K. D. Eisenach, B. Gicquel, et al. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for standardized methodology. J. Clin. Microbiol. 31:406-409.[Abstract/Free Full Text]
    23. 23
  23. Yuen, L. K. W., D. Leslie, and P. J. Coloe. 1999. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J. Clin. Microbiol. 37:3844-3850.[Abstract/Free Full Text]

Journal of Clinical Microbiology, May 2003, p. 2209-2212, Vol. 41, No. 5
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.5.2209-2212.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Evans, J., Stead, M. C., Nicol, M. P., Segal, H. (2009). Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 63: 11-16 [Abstract] [Full Text]  
  • Soudani, A., Hadjfredj, S., Zribi, M., Masmoudi, A., Messaoud, T., Tiouri, H., Fendri, C. (2007). Characterization of Tunisian Mycobacterium tuberculosis Rifampin-Resistant Clinical Isolates. J. Clin. Microbiol. 45: 3095-3097 [Abstract] [Full Text]  
  • Hillemann, D., Rusch-Gerdes, S., Richter, E. (2007). Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens. J. Clin. Microbiol. 45: 2635-2640 [Abstract] [Full Text]  
  • Afanas'ev, M. V., Ikryannikova, L. N., Il'ina, E. N., Sidorenko, S. V., Kuz'min, A. V., Larionova, E. E., Smirnova, T. G., Chernousova, L. N., Kamaev, E. Yu., Skorniakov, S. N., Kinsht, V. N., Cherednichenko, A. G., Govorun, V. M. (2007). Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. J Antimicrob Chemother 59: 1057-1064 [Abstract] [Full Text]  
  • Chan, R. C. Y., Hui, M., Chan, E. W. C., Au, T. K., Chin, M. L., Yip, C. K., AuYeang, C. K. W., Yeung, C. Y. L., Kam, K. M., Yip, P. C. W., Cheng, A. F. B. (2007). Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 59: 866-873 [Abstract] [Full Text]  
  • Ma, X., Wang, H., Deng, Y., Liu, Z., Xu, Y., Pan, X., Musser, J. M., Graviss, E. A. (2006). rpoB Gene Mutations and Molecular Characterization of Rifampin-Resistant Mycobacterium tuberculosis Isolates from Shandong Province, China.. J. Clin. Microbiol. 44: 3409-3412 [Abstract] [Full Text]  
  • Murphy, C. K., Mullin, S., Osburne, M. S., van Duzer, J., Siedlecki, J., Yu, X., Kerstein, K., Cynamon, M., Rothstein, D. M. (2006). In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 827-834 [Abstract] [Full Text]  
  • Zhang, M., Yue, J., Yang, Y.-p., Zhang, H.-m., Lei, J.-q., Jin, R.-l., Zhang, X.-l., Wang, H.-h. (2005). Detection of Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis Isolates from China. J. Clin. Microbiol. 43: 5477-5482 [Abstract] [Full Text]  
  • Jou, R., Chen, H.-Y., Chiang, C.-Y., Yu, M.-C., Su, I.-J. (2005). Genetic Diversity of Multidrug-Resistant Mycobacterium tuberculosis Isolates and Identification of 11 Novel rpoB Alleles in Taiwan. J. Clin. Microbiol. 43: 1390-1394 [Abstract] [Full Text]  
  • Herrera-Leon, L., Molina, T., Saiz, P., Saez-Nieto, J. A., Jimenez, M. S. (2005). New Multiplex PCR for Rapid Detection of Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 49: 144-147 [Abstract] [Full Text]  
  • Yam, W. C., Tam, C. M., Leung, C. C., Tong, H. L., Chan, K. H., Leung, E. T. Y., Wong, K. C., Yew, W. W., Seto, W. H., Yuen, K. Y., Ho, P. L. (2004). Direct Detection of Rifampin-Resistant Mycobacterium tuberculosis in Respiratory Specimens by PCR-DNA Sequencing. J. Clin. Microbiol. 42: 4438-4443 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yue, J.
Right arrow Articles by Wang, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yue, J.
Right arrow Articles by Wang, H.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»